Wuppertal, Germany

Siegbert Hebisch

This inventor holds 31 USPTO granted patents, primarily in Dihydropyridine Compounds. Top assignee: Bayer Aktiengesellschaft. Active years: 1990-1998.


% Patents Active = 100.0

Average Co-Inventor Count = 7.7

ph-index = 7

Forward Citations = 101(Granted Patents)


Location History:

  • Oberhausen, DE (1990 - 1991)
  • Wuppertal, DE (1991 - 1995)
  • Bottrop, DE (1996 - 1998)

Company Filing History:


Years Active: 1990-1998

Loading Chart...
Areas of Expertise:
Dihydropyridines
Quinolyl Derivatives
Cardiovascular Activity
Pharmaceuticals
Medicaments
Cinnoline
Nitro-Phenyl Compounds
Amino Compounds
Cyclohexenecarboxylates
Esters
Intermediate Compounds
Basic Amides
31 patents (USPTO):Explore Patents

Title: The Innovative Journey of Inventor Siegbert Hebisch

Introduction: Siegbert Hebisch, a proficient inventor hailing from Wuppertal, Germany, has left a remarkable imprint in the field of patents with an impressive total of 31 patents to his name.

Latest Patents: Among his latest patents is the groundbreaking invention of 4-bicyclically substituted dihydropyridines, essential components in medicaments designed for the treatment of cardiovascular diseases. Additionally, he introduced 3-quinolyl-substituted dihydropyridines, contributing significantly to the advancement of treatments for cardiovascular ailments.

Career Highlights: Siegbert Hebisch's innovative spirit found a home in renowned companies such as Bayer Aktiengesellschaft, known simply as Bayer, where he contributed significantly to cutting-edge research and development initiatives. His keen insights and dedication have played a crucial role in shaping the landscape of pharmaceutical inventions.

Collaborations: Throughout his illustrious career, Siegbert Hebisch collaborated with valued peers such as Martin Bechem and Rainer Gross, synergizing their talents to bring forth pioneering inventions and patents in the realm of pharmacology.

Conclusion: The inventive genius of Siegbert Hebisch stands as a testament to his unwavering commitment to driving innovation in the field of pharmaceuticals. His contributions have not only enriched the patent landscape but have also paved the way for advancements in the treatment of cardiovascular diseases, leaving a lasting impact on the industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…